| Drug General Information |
| Drug ID |
D0S5TT
|
| Former ID |
DIB000701
|
| Drug Name |
ACE-435
|
| Synonyms |
RAP-435; TGF beta protein superfamily signaling inhibitor (cancer cachexia/metabolic disease/age-related muscle loss), Acceleron
|
| Indication |
Cachexia [ICD9: 799.4; ICD10:R64]
|
Investigative |
[1]
|
|---|
| Company |
Acceleron Pharma Inc
|
| Target and Pathway |
| Target(s) |
TGF-beta receptor type I |
Target Info |
Inhibitor |
[1]
|
|---|
|
KEGG Pathway
|
MAPK signaling pathway
|
|
Cytokine-cytokine receptor interaction
|
|
FoxO signaling pathway
|
|
Endocytosis
|
|
TGF-beta signaling pathway
|
|
Osteoclast differentiation
|
|
Hippo signaling pathway
|
|
Adherens junction
|
|
Chagas disease (American trypanosomiasis)
|
|
Hepatitis B
|
|
HTLV-I infection
|
|
Pathways in cancer
|
|
Colorectal cancer
|
|
Pancreatic cancer
|
|
Chronic myeloid leukemia
|
|
PANTHER Pathway
|
TGF-beta signaling pathway
|
|
Pathway Interaction Database
|
Glypican 1 network
|
|
ALK1 signaling events
|
|
Beta5 beta6 beta7 and beta8 integrin cell surface interactions
|
|
TGF-beta receptor signaling
|
|
Reactome
|
TGF-beta receptor signaling activates SMADs
|
|
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
|
|
SMAD2/3 Phosphorylation Motif Mutants in Cancer
|
|
SMAD2/3 MH2 Domain Mutants in Cancer
|
|
TGFBR2 Kinase Domain Mutants in Cancer
|
|
TGFBR1 KD Mutants in Cancer
|
|
TGFBR1 LBD Mutants in Cancer
|
|
WikiPathways
|
TGF Beta Signaling Pathway
|
|
p38 MAPK Signaling Pathway
|
|
MAPK Signaling Pathway
|
|
TGF beta Signaling Pathway
|
|
Extracellular vesicle-mediated signaling in recipient cells
|
|
Cardiac Hypertrophic Response
|
|
Signaling by TGF-beta Receptor Complex
|
|
Integrated Pancreatic Cancer Pathway
|
|
Integrated Breast Cancer Pathway
|
| References |
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1788). |
|---|
